The present invention relates to a composition comprising glucose oligosaccharide and a process for making such. The present invention further relates to a composition comprising glucose oligosaccharide for use in the treatment of an animal. The present invention further relates to the use of a composition comprising glucose oligosaccharide to improve the growth performance of an animal. The present invention further relates to the use of a composition comprising glucose oligosaccharide to improve the immune system modulation of an animal.

The present invention relates to a composition comprising glucose oligosaccharide and a process for making such. The present invention further relates to a composition comprising glucose oligosaccharide for use in the treatment of an animal. The present invention further relates to the use of a composition comprising glucose oligosaccharide to improve the growth performance of an animal. The present invention further relates to the use of a composition comprising glucose oligosaccharide to improve the immune system modulation of an animal.

The present disclosure provides compounds, combinations, methods, and kits for the treatment of aging and age related disorders and related mediums.

The present disclosure provides compounds, combinations, methods, and kits for the treatment of aging and age related disorders and related mediums.

The present invention provides compositions and methods involving stable omega-3 diglyceride oil-in-water emulsions for acute therapy to treat and/or prevent tissue or organ injury. The compositions provide protection from cellular death, and find use in patients in need of neuroprotection. For example, the compositions find use in treating ischemia reperfusion injuries, such as ischemic stroke. The compositions further find use for treatment of traumatic injuries, such as traumatic brain injury or spinal cord injury, among others. The compositions have a large time window by which they are effective after onset of traumatic or ischemic injury (e.g., after onset of stroke), and may be administered in conjunction with other therapies.

The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Described herein are methods for preventing non-insulted cell damage during a subject's exposure to radiation. In some embodiments, the method can include administering an amount of poloxamer 188 or a pharmaceutical formulation thereof to a subject prior to exposure to an insult.

Described herein are methods for preventing non-insulted cell damage during a subject's exposure to radiation. In some embodiments, the method can include administering an amount of poloxamer 188 or a pharmaceutical formulation thereof to a subject prior to exposure to an insult.

The invention relates to a hybrid proteinaceous molecule comprising at least two proteins capable of inhibiting the activity of at least one antibiotic, the proteins each having different biochemical properties and being bonded to one another. The hybrid proteinaceous molecule inhibits the activity of a least one antibiotic in order to reduce the intestinal side effects of antibiotics, such as severe diarrhoea caused by the antibiotics, and nosocomial infections secondary to parenteral antibiotic therapy.